RT Journal Article
SR Electronic
T1 AN AFFORDABLE ANTI-SARS-COV-2 SPIKE ELISA TEST FOR EARLY DETECTION OF IgG SEROCONVERSION SUITED FOR LARGE-SCALE SURVEILLANCE STUDIES IN LOW-INCOME COUNTRIES
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.13.20152884
DO 10.1101/2020.07.13.20152884
A1 Alvim, Renata G. F.
A1 Lima, Tulio M.
A1 Rodrigues, Danielle A. S.
A1 Marsili, Federico F.
A1 Bozza, Vicente B. T.
A1 Higa, Luiza M.
A1 Monteiro, Fabio L.
A1 Leitão, Isabela C.
A1 Carvalho, Renato S.
A1 Galliez, Rafael M.
A1 Castineiras, Terezinha M. P. P.
A1 Nobrega, Alberto
A1 Travassos, Leonardo H.
A1 Ferreira, Orlando C.
A1 Tanuri, Amilcar
A1 Vale, André M.
A1 Castilho, Leda R.
YR 2020
UL http://medrxiv.org/content/early/2020/07/15/2020.07.13.20152884.abstract
AB We describe a cost-effective, scalable technology to produce SARS-COV-2 spike (S) protein based on stable expression in HEK293 cells, and its use to develop a highly specific and sensitive ELISA test. The assay allows early detection of anti-S IgG seroconversion and endpoint titers correlate with virus neutralization. The low-cost S-antigen production, together with sample collection by finger prick and dried blood spots, allowed the development of a half-dollar test that fits the urgent need for large-scale serological surveillance in low-income countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors gratefully acknowledge Dr. B. Graham and Dr. K. Corbett (VRC/NIAID/NIH, USA) for sharing the plasmid encoding the S protein gene construct, and Prof. E. Durigon (USP, Brazil) for providing the SARS-COV-2 isolate used in neutralization assays. This work was supported by the Brazilian research funding agencies FAPERJ, CNPq, CAPES and Instituto Serrapilheira.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:According to a protocol approved by the national ethics committee (CONEP, Brazil; protocol #30161620000005257; review #3953368), subjects were initially interviewed and, if they accepted to participate, they signed the informed consent, answered a questionnaire (addressing demographic data, onset and type of symptoms, history of travel abroad, among other information) and had blood (venous blood and/or finger prick) and nasopharyngeal swab collected.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data of all experiments are available upon request.